{
    "id": 17638,
    "fullName": "PDPK1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PDPK1 over exp indicates an over expression of the Pdpk1 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5170,
        "geneSymbol": "PDPK1",
        "terms": [
            "PDPK1",
            "PDK1",
            "PDPK2",
            "PDPK2P",
            "PRO0461"
        ]
    },
    "variant": "over exp",
    "createDate": "02/03/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4396,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BX-795 inhibited the growth transformed human cells over expressing Pdpk1 (PMID: 23887393).",
            "molecularProfile": {
                "id": 17943,
                "profileName": "PDPK1 over exp"
            },
            "therapy": {
                "id": 3467,
                "therapyName": "BX-795",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4479,
                    "pubMedId": 23887393,
                    "title": "PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23887393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8883,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pdpk1 (Pdk1) over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",
            "molecularProfile": {
                "id": 26511,
                "profileName": "PDPK1 over exp PIK3CA H1047R"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6782,
                    "pubMedId": 27604488,
                    "title": "Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27604488"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17943,
            "profileName": "PDPK1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26511,
            "profileName": "PDPK1 over exp PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}